A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

NCT03381196 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

553

Enrollment

INDUSTRY

Sponsor class

Stopped Based on interim Analysis outcome being futile for FLZ3001; decision was taken to stop (early terminate) both FLZ3001/3002. There was no safety concern.

Conditions

Influenza A

Interventions

DRUG: Pimodivir 600 mg
DRUG: Placebo
OTHER: SOC Treatment

Sponsor

Janssen Research & Development, LLC